A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Status:
Recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.

Phase 2

Alumis Inc